Editas Medicine, Inc.
EDIT
NASDAQ·Healthcare·Biotechnology·Mkt cap $495.7M
$3.23
▲ +4.87%
P/E
-4.32
Mkt Cap
$495.7M
52-Wk Range
$1.66–$4.54
52-Week Range
$1.66 - $4.54
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 15.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CRISPR gene editing platform
- Advanced clinical pipeline targeting rare diseases
- Strategic research collaborations
- Expertise in genetic medicine development
Bear Case
1 risk
- High volatility (beta 2.1). Larger-than-normal price swings expected.
Growth
Revenue decline expected
Advancing clinical trials for genetic therapies
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+21.9% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying EDIT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 5, 2026
Reported EPS of -$0.15 vs -$0.27 consensus (+44.5% surprise). Revenue of $11.9M vs $2.8M expected (+317.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+44.5%
Revenue trend · last 8Q
—
-49%
+310%
+597%
+12266%
-19%
-39%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$61.0K
$30.6M
$4.7M
$3.6M
$7.5M
$24.7M
$2.8M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Chardan Capital · $4.00 · May 5, 2026
vs Industry
How EDIT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related